Interview Summary

Application No.

Applicant(s)

CORONA VILLEGAS ET AL.

Examiner

And U. Desai, Ph.D.

Applicant(s)

CORONA VILLEGAS ET AL.

1653

	- La contraction of the contract
All participants (applicant, applicant's representative, PTC	O personnel):
(1) <u>Anand U. Desai, Ph.D.</u> .	(3)
(2) <u>Ms. Laura Vogel</u> .	(4)
Date of Interview: 12 September 2006.	
Type: a)⊠ Telephonic b)□ Video Conference c)□ Personal [copy given to: 1)□ applicant	2) applicant's representative]
Exhibit shown or demonstration conducted: d) Yes If Yes, brief description:	e)⊠ No.
Claim(s) discussed: 3.	
Identification of prior art discussed: <u>Discussed the sequented</u> 115.	nce search of the polypeptide represented as SEQ ID NO:
Agreement with respect to the claims f) was reached.	g) was not reached. h) N/A.
how SEQ ID NO: 115 is a chemically distinct compound. 112, 1 st paragraph written description for isolated nucleic NO: 115. Discussed how SEQ ID NO: 115 is drawn to an polypeptide.	n/election of SEQ ID NO: 115. Discussed MPEP 2434 and Discussed possible amendments to the claims. Discussed acid sequences having certain percent identity to SEQ ID isolated nucleic acid sequence and not an isolated
(A fuller description, if necessary, and a copy of the amer allowable, if available, must be attached. Also, where no allowable is available, a summary thereof must be attached.	
GIVEN A NON-EXTENDABLE PERIOD OF THE LONGER	ne last Office action has already been filed, APPLICANT IS R OF ONE MONTH OR THIRTY DAYS FROM THIS ITERVIEW SUMMARY FORM, WHICHEVER IS LATER, TO
Examiner Note: You must sign this form unless it is an	A

Attachment to a signed Office action.

Examiner's signature, if required